TNYA News and Press, Tenaya Therapeutics Inc. From 04/20/23

2023-04-20 14:46:29 ET Shares of the clinical-stage gene therapy company Tenaya Therapeutics (NASDAQ: TNYA) rose by a staggering 49% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence . The biotech's shares...

2023-04-20 12:54:06 ET Gainers: Augmedix ( AUGX ) +68% . CNS Pharmaceuticals ( CNSP ) +65% . United Insurance Holdings ( UIHC ) +49% . Tenaya Therapeutics ( TNYA ) +27% . Brenmiller Energy ( BNRG ) +23% . VCI Global Limited (...

2023-04-10 02:43:26 ET Summary Tenaya Therapeutics is a developer of therapies for heart diseases. TNYA is nearly a decade old, but its pipeline is very early stage. Investors should wait for more data and some basic derisking. Tenaya Therapeutics ( TNYA ) is an ...

2023-03-09 10:01:05 ET Gainers: Ocean Biomedical OCEA +57% . Avenue Therapeutics ( ATXI ) +21% . Unicycive Therapeutics ( UNCY ) +19% . Assertio ( ASRT ) +12% . Immuneering ( IMRX ) +11% . Losers: InVivo Therapeutics NVIV ...

2023-03-08 18:08:57 ET Tenaya Therapeutics press release ( NASDAQ: TNYA ): Q4 GAAP EPS of -$0.61 beats by $0.03 . As of December 31, 2022, cash, cash equivalents and investments in marketable securities (current and noncurrent) were $204.2 million. Tenaya expects curre...

TN-201 IND Cleared in January; Plan to Begin Phase 1b Dosing in MYBPC3-associated HCM Patients in Third Quarter 2023 Dosing Commenced in Multiple-Ascending Dose Stage of First-In-Human Clinical Trial of TN-301; Data Anticipated in Second Half 2023 2022 Year End Cash and Invest...

Stock Market Down? Insiders Are Buying Penny Stocks We’ve talked about how penny stocks tend to move independently of the broader markets. But there has been particular attention placed on specific stocks that insiders seem to like. There’s no guarantee that buying from corp...

Tenaya Therapeutics ( NASDAQ: TNYA ) is up ~6% in after-hours trading on Thursday after a member of the board of directors made a large acquisition of additional shares. David Goeddel, managing partner at The Column Group, bought 49,463 shares on Jan. 17 at an average price of $2....

Summary Shares of heart therapy concern Tenaya Therapeutics, Inc. are down 85% from their IPO pricing in July 2021 as a dearth of catalysts is to blame. The company’s lead program (CN-301) just entered the clinic in a dose finding Phase 1 study on healthy subjects with results ex...

Phase 1b Clinical Trial for TN-201 in MYBPC3-associated HCM Patients Expected to Begin Dosing in Third Quarter 2023; Data Anticipated in 2024 Data from First-in-Human Clinical Trial of TN-301 Anticipated in Second Half 2023 TN-401 IND Submission Planned in Second Half 2023 ...